Canada: Court of Appeal Tempers "Promise of the Patent" Doctrine

Last Updated: July 27 2013
Article by Livia Aumand

On July 24, 2013, the Federal Court of Appeal overturned the 2011 trial decision that had invalidated sanofi’s patent for the blockbuster drug Plavix® (clopidogrel bisulfate) (sanofi-aventis v. Apotex Inc., 2013 FCA 186). In concurring sets of reasons, both Justice Pelletier (concurred in by Justice Noël) and Justice Gauthier held that the trial judge erred in finding the patent to be invalid on the grounds of inutility and obviousness. The focus of both sets of Reasons was on the issue of utility, which is currently a topic of great interest in Canadian patent law.

The Plavix® patent is a selection patent, meaning that it identified an inventive selection over a prior art patent.   In this case, the prior art patent (the “genus patent”) covered a large genus of compounds having platelet aggregation inhibiting activity. The compounds of the genus patent were racemates, meaning that they are each comprised of 50:50 mixtures of two structurally different compounds, called enantiomers. The inventors of the Plavix® patent had separated one of these racemates into its two enantiomers and found that they had distinct properties. One of the enantiomers, clopidogrel, had all the platelet aggregation inhibiting activity of the racemate and was less toxic and better tolerated than the racemate and the other enantiomer.  

The Plavix® patent was first litigated in Canada under the Patented Medicines (Notice of Compliance) Regulations. Apotex Inc. had alleged that the patent was invalid on the grounds of anticipation, double patenting and obviousness. Sanofi was successful in defending the patent on each of these grounds before every level of court in Canada, including the Supreme Court (Apotex Inc. v. Sanofi-Synthelabo Canada Inc., 2008 SCC 61, [2008] 3 SCR 265). 

Following the Supreme Court’s decision, Apotex Inc. began an action in the Federal Court to impeach the Plavix® patent. Sanofi then commenced an action for infringement of the patent, based on Apotex’s importation into Canada and exportation out of Canada of clopidogrel. These two actions were consolidated and heard by the trial judge in 2011, who found the patent to be invalid. Although the trial judge also found that Apotex had infringed the patent, that finding was overtaken by his conclusion that the patent was invalid.

In addition to the same grounds of invalidity it had argued before the Supreme Court, Apotex raised the ground of inutility for the first time. The trial judge’s finding of inutility turned on his construction of the “promise of the patent” as being that clopidogrel could be used in humans. While this was found to be soundly predicted, the trial judge held that the inventors had not disclosed enough of their factual basis and line of reasoning to satisfy the doctrine of sound prediction.

The doctrine of the “promise of the patent” is unique to Canadian patent law. Simply put, the promise doctrine holds that if a patent promises a particular utility, the patentee will have had to demonstrate or soundly predict that utility by the Canadian filing date. In recent years, several patents have been invalidated by the Federal Courts on the basis that the patentee had failed to fulfill the promise of the patent by the relevant date.

Both Justice Pelletier and Justice Gauthier brought some welcome clarification to the relationship between the requirement that an invention be useful and the promise doctrine.  First, the Court cautioned that, since not every patent has a promise, judges should not try to read a promise into a patent where none exists. A patentee should only be required to satisfy the promise doctrine where the patent makes an explicit promise of a specific result. 

The Court of Appeal held that it was in his construction of the promise that the trial judge erred in his utility analysis. The trial judge had wrongly based his construction of the promise on “inferences” that clopidogrel could be used in humans, rather than on explicit language in the specification. In contrast, the patent had made clear and unambiguous statements with respect to clopidogrel’s advantages over the genus patent, which the trial judge held had been demonstrated by the filing date. Thus, the Court of Appeal held that the patent was not invalid for lack of utility.

In coming to the conclusion that the patent did not promise that clopidogrel would be useful in humans, both Justices Pelletier and Gauthier introduced some welcome practicality into the construction of the promise. Justice Pelletier noted that while the ultimate goal of those in the pharmaceutical industry would have been to use clopidogrel in humans to treat disorders related to platelet aggregation, this goal or hope should not be equated to a promise.   

Justice Gauthier also identified the danger of equating statements in the patent referring to potential applications of an invention to an explicit promise of a specific result. She explained that Canadian patents are often based on European priority applications, which (unlike the requirements under Canadian patent law) are required to state in their disclosures how their inventions are capable of industrial application. Thus, the Court should take care to distinguish between statements made in the patent’s disclosure and statements of utility made in the claims.

The approach by the Court of Appeal to the issue of the promise doctrine provides helpful guidance for both litigants and the Courts. Most importantly, one should not strain to find a promise where there is no explicit language of a promise in the specification. As stated by Justice Pelletier, “… Courts should not strive to find ways to defeat otherwise valid patents.”  

The Court also overturned the trial judge’s obviousness finding on the basis that the trial judge incorrectly focused on whether the method of separating the enantiomers was obvious, as opposed to whether the beneficial properties of clopidogrel over the racemate and the other enantiomer would have been obvious. Further, the trial judge had not addressed why the person skilled in the art would have started with the racemate in the first place, given the hundreds of thousands of compounds disclosed in the genus patent.

Finally, the Court rejected Apotex’ defences that would have limited sanofi’s recovery for Apotex’ importation and exportation of clopidogrel. As the issues of  liability and quantification of damages were bifurcated, the latter issue has been remanded to the trial judge.

Counsel for the appellants sanofi-aventis and Bristol-Myers Squibb Sanofi Pharmaceuticals Holding Partnership were Gowlings lawyers Anthony Creber, Marc Richard and Livia Aumand.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Similar Articles
Relevancy Powered by MondaqAI
Bereskin & Parr LLP
In association with
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Bereskin & Parr LLP
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of

To Use you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions